First-line induction chemotherapy with high-dose methotrexate versus teniposide in patients with newly diagnosed primary central nervous system lymphoma: a retrospective, multicenter cohort studyKaili Zhong, Huilai Zhang, Mingzhi Zhang et al.|BMC Cancer|2023Cited by 7
A multi-center, open-label, randomized, parallel-controlled phase II study comparing pharmacokinetic, pharmacodynamics and safety of ripertamab (SCT400) to rituximab (MabThera� in patients with CD20-positive B-cell non-Hodgkin lymphomaXiaohong Han, Yuankai Shi, Mingzhi Zhang et al.|Chinese Journal of Cancer Research|2022Cited by 5